Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Payables (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Payables for 7 consecutive years, with $4.3 million as the latest value for Q4 2025.

  • Quarterly Payables fell 20.84% to $4.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Dec 2025, down 20.84% year-over-year, with the annual reading at $4.3 million for FY2025, 20.84% down from the prior year.
  • Payables hit $4.3 million in Q4 2025 for Allogene Therapeutics, up from $3.7 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $14.9 million in Q1 2021 to a low of $3.7 million in Q3 2025.
  • Historically, Payables has averaged $8.8 million across 5 years, with a median of $9.2 million in 2022.
  • Biggest five-year swings in Payables: skyrocketed 106.63% in 2021 and later plummeted 62.5% in 2025.
  • Year by year, Payables stood at $10.3 million in 2021, then soared by 35.45% to $13.9 million in 2022, then crashed by 57.54% to $5.9 million in 2023, then decreased by 8.53% to $5.4 million in 2024, then dropped by 20.84% to $4.3 million in 2025.
  • Business Quant data shows Payables for ALLO at $4.3 million in Q4 2025, $3.7 million in Q3 2025, and $4.9 million in Q2 2025.